Title

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
A Phase I/II, Randomized, Prospective, Controlled, Multi-center, Open-label, Two Arm Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Liver Bleeding During Elective Surgery
  • Phase

    Phase 1/Phase 2
  • Study Type

    Interventional
  • Status

    Recruiting
  • Study Participants

    20
The Study investigates a new product, sFilm-FS, aimed to help controlling body fluid leakage in general surgery procedures, proposing its use as an adjunct to hemostasis and/or sealing.
Many products have been developed as adjuncts to hemostasis in bleeding situations where traditional methods such as suture, clips or energy-based coagulation are ineffective or impractical.

Many products are not as effective in the presence of active and/or brisk bleeding since the lack of sufficient adhesion strength allows forceful bleeding to simply "float" the products away from the bleeding tissue, prior to the achievement of full hemostasis.

The Study investigates a new product, sFilm-FS, aimed to help the control of body fluid leakage in general surgery procedures, proposing its use as an adjunct to hemostasis and/or sealing.
Study Started
May 12
2021
Primary Completion
Dec 01
2022
Anticipated
Study Completion
Dec 01
2022
Anticipated
Last Update
Mar 18
2022

Combination Product sFilm-FS [thrombin, fibrinogen (human) (RiaSTAP), calcium chloride]

sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.

Combination Product TACHOSIL® [fibrinogen (human) (RiaSTAP), thrombin]

TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.

sFilm-FS Experimental

TACHOSIL® Active Comparator

Criteria

Inclusion Criteria:

Patients (males or females) aged ≥ 18 years old.
Patients requiring elective open hepatic surgery.
Hemoglobin ≥ 8.0 g/dL within 24 hours prior to surgical procedure.
Patients understanding the nature of the study and providing their informed consent prior to participation.
Patients willing to participate in the study and able to attend the visits and procedures foreseen by study protocol.
Patients with a target bleeding site (TBS) identified by the Investigator during hepatic surgery (intra-operative inclusion criteria).

Exclusion Criteria:

Patients undergoing a re-operative procedure.
Patients having undergone a therapeutic surgical procedure within 30 days from the study enrolment.
Patients with a severe coagulopathy defined as INR > 2.0.
Patients with platelet count <50,000 x109 PLT/L at the screening (ref. 11).
Patients admitted to trauma surgery.
Transplant patients due to fulminant hepatic failure.
Patients with known or suspected allergy or hypersensitivity to blood products or to one of the components of sFilm-FS or the active-comparator.
Patients with anesthesia risk judged to be higher than ASA3 by the Investigator.
Patients with at least one of the following concomitant conditions: severe co-morbid conditions known to pose a high risk for surgery and adequate recovery (i.e. liver cirrhosis with Child-Pugh score B or C, cholestasis, heart diseases), immunodeficiency diseases, blood clotting disorders, any conditions known to effect wound healing (i.e. collagen vascular disease), known or current alcohol or drug abusers.
Patients being treated with at least one of the following treatments: antibiotic therapy for active infection, fibrin sealants, systemic steroids or immunosuppressive agents.
Patients who are participating or have participated in other clinical studies within the 30 days before the study enrolment.
Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical study and for three months later.

Female patients of childbearing age (less than 24 months after the last menstrual cycle) who do not use adequate contraception.

Intra-operative exclusion criteria:

Patients identified with a TBS with major arterial bleeding requiring suture or mechanical ligation.
Patients identified by the Investigator to have intra-operative bleeding from large defects in large arteries or veins, requiring repair.
Patients identified by the Investigator to have intra-operative findings that may preclude conduct of study procedure.
Patients having an active local infection in the anatomic surgical area.
Patients with occurrence of major intra-operative complications that require resuscitation or deviation from the planned surgical procedure.
Patients with bleeding site in or near to foramina in bone.
No Results Posted